ReviewCurrent oncology reports2014
Current status of molecular biomarkers in endometrial cancer.
Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The Prognostic Significance and Co-Expression of Fibroblast Growth Factor Receptor 2 and c-Met in Endometrial Cancer.International journal of women's health · 2025Article
- Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation.Indian journal of surgical oncology · 2022Article
- Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer.Clinical Medicine Insights. Oncology · 2022Article
- In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer.Cell reports. Medicine · 2021Article
- Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.Oncology reports · 2020Observational
- Prognostic molecular biomarkers in endometrial cancer: A review.Journal of cancer research & therapy · 2019Article
- Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study.Journal of gynecologic oncology · 2019Observational
- Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.Current oncology (Toronto, Ont.) · 2019Observational
- Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.European radiology · 2019Review
- The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.Journal of gynecologic oncology · 2019Article
- Metabolomic prediction of endometrial cancer.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues.Scientific reports · 2017Article
- FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology · 2017Article
- Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.Oncotarget · 2017Article
- Article
- Microsatellite polymorphism in the P1 promoter region of the IGF‑1 gene is associated with endometrial cancer.Molecular medicine reports · 2016Article
- Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.Nature reviews. Clinical oncology · 2016Review
- Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.Oncotarget · 2016Article
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.
Indexed as
Identifiers
25064587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.